Novavax, Inc. (NVAX)Healthcare | Biotechnology | Gaithersburg, United States | NasdaqGS
8.91 USD
-0.42
(-4.502%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:29 a.m. EDT
The investment case here is fundamentally broken. Novavax is a biotech company with no dividend to speak of, currently trading with negative earnings and a crushing -79% revenue decline. The balance sheet shows negative book value and deteriorating operating margins, indicating the core business is failing to generate sustainable cash flow. While the stock price has recently stabilized near the $9 level, the long-term trajectory is a disaster, having lost over 95% of its value over the last nine years. The recent price action is merely a pause in a secular decline, not a reversal. Options activity confirms this pessimism, with traders buying deep out-of-the-money puts to hedge against further drops rather than betting on a rally. Until the company demonstrates a path to profitability and revenue recovery, this remains a high-risk speculative vehicle unsuitable for serious capital allocation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.142516 |
| AutoARIMA | 0.149756 |
| AutoETS | 0.149757 |
| AutoTheta | 0.265570 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.036 |
| Excess Kurtosis | 0.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.669 |
| Market Cap | 1,465,143,552 |
| Forward P/E | -16.42 |
| Beta | 2.43 |
| Profit Margins | -14.73% |
| Website | https://www.novavax.com |
As of July 11, 2026, 5:29 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $7-$8) compared to negligible call volume. While there is some speculative call flow at distant strikes ($13-$16), the overwhelming capital allocation is defensive, suggesting a belief that the stock will struggle to break key resistance levels soon.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.33859396 |
| Address1 | 21 Firstfield Road |
| All Time High | 331.68 |
| All Time Low | 3.53 |
| Ask | 11.37 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 4,493,510 |
| Average Daily Volume3 Month | 4,852,591 |
| Average Volume | 4,852,591 |
| Average Volume10Days | 4,493,510 |
| Beta | 2.427 |
| Bid | 8.1 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | -0.88 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.91 |
| Current Ratio | 2.484 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.27 |
| Day Low | 8.805 |
| Display Name | Novavax |
| Dividend Date | 1,557,446,400 |
| Earnings Call Timestamp End | 1,778,070,600 |
| Earnings Call Timestamp Start | 1,778,070,600 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | 59,532,000 |
| Ebitda Margins | 0.09983 |
| Enterprise To Ebitda | 16.292 |
| Enterprise To Revenue | 1.626 |
| Enterprise Value | 969,869,632 |
| Eps Current Year | -0.41691 |
| Eps Forward | -0.54261 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.2854 |
| Fifty Day Average Change | -0.37540054 |
| Fifty Day Average Change Percent | -0.04042912 |
| Fifty Two Week Change Percent | 33.859398 |
| Fifty Two Week High | 11.97 |
| Fifty Two Week High Change | -3.0600004 |
| Fifty Two Week High Change Percent | -0.25563914 |
| Fifty Two Week Low | 6.2 |
| Fifty Two Week Low Change | 2.71 |
| Fifty Two Week Low Change Percent | 0.4370968 |
| Fifty Two Week Range | 6.2 - 11.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 818,173,800,000 |
| Float Shares | 141,467,758 |
| Forward Eps | -0.54261 |
| Forward P E | -16.420633 |
| Free Cashflow | 58,573,936 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 749 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.27493998 |
| Gross Profits | 163,956,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.050780002 |
| Held Percent Institutions | 0.69435996 |
| Implied Shares Outstanding | 164,438,119 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.novavax.com/go.cfm?do=Stock.GetQuote |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,557,446,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Novavax, Inc. |
| Market | us_market |
| Market Cap | 1,465,143,552 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_350381 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -87,835,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,534,207,650 |
| Number Of Analyst Opinions | 9 |
| Open | 9.12 |
| Operating Cashflow | -91,556,000 |
| Operating Margins | -0.071890004 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.32 |
| Phone | 240 268 2000 |
| Pre Market Change | 0.03999996 |
| Pre Market Change Percent | 0.44893336 |
| Pre Market Price | 8.95 |
| Pre Market Time | 1,784,019,782 |
| Previous Close | 9.33 |
| Price Eps Current Year | -21.37152 |
| Price Hint | 2 |
| Price To Book | -10.125 |
| Price To Sales Trailing12 Months | 2.4569013 |
| Profit Margins | -0.14729 |
| Quick Ratio | 2.376 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.42 |
| Regular Market Change Percent | -4.50161 |
| Regular Market Day High | 9.27 |
| Regular Market Day Low | 8.805 |
| Regular Market Day Range | 8.805 - 9.27 |
| Regular Market Open | 9.12 |
| Regular Market Previous Close | 9.33 |
| Regular Market Price | 8.91 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 3,849,135 |
| Return On Assets | 0.0199 |
| Revenue Growth | -0.791 |
| Revenue Per Share | 3.669 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 164,438,119 |
| Shares Percent Shares Out | 0.2786 |
| Shares Short | 45,809,886 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 45,965,363 |
| Short Name | Novavax, Inc. |
| Short Percent Of Float | 0.2804 |
| Short Ratio | 9.99 |
| Source Interval | 15 |
| State | MD |
| Symbol | NVAX |
| Target High Price | 25.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 14.11333 |
| Target Median Price | 16.02 |
| Total Cash | 790,332,032 |
| Total Cash Per Share | 4.806 |
| Total Debt | 295,057,984 |
| Total Revenue | 596,337,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.54265 |
| Two Hundred Day Average Change | 0.36734962 |
| Two Hundred Day Average Change Percent | 0.043001834 |
| Type Disp | Equity |
| Volume | 3,849,135 |
| Website | https://www.novavax.com |
| Zip | 20,878 |